IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11602583 B1

PDFFull Text
Date of Patent:
Mar. 14, 2023

Filed:

Feb. 12, 2021

Direct sodium removal method, solution and apparatus to reduce fluid overload in heart failure patients

Applicant:

Sequana Medical NV, Ghent, BE;

Inventors:

Neil Inhaber, Westborough, MA (US);

Noel Johnson, Saratoga, CA (US);

Dirk Fengels, Ballwil, CH;

Ian Crosbie, London, GB;

Assignee:

Sequana Medical NV, Sint-Denijs Westrem, BE;

Attorneys:

Eversheds Sutherland (US) LLP

Nicola A. Pisano

Christopher C. Bolten

Primary Examiner:

Robert A Wax

Assistant Examiner:

Randeep Singh

Int. Cl.
CPC ...
A61M 1/28 (2006.01); A61P 7/08 (2006.01); A61K 33/14 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 31/7004 (2006.01); A61K 31/716 (2006.01); A61M 27/00 (2006.01); A61M 31/00 (2006.01); A61L 2/00 (2006.01);
U.S. Cl.
CPC ...
A61M 1/282 (2014.02); A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 31/7004 (2013.01); A61K 31/716 (2013.01); A61K 33/14 (2013.01); A61M 1/28 (2013.01); A61M 1/285 (2013.01); A61M 1/287 (2013.01); A61M 27/002 (2013.01); A61M 31/002 (2013.01); A61P 7/08 (2018.01); A61L 2/0047 (2013.01); A61L 2202/21 (2013.01); A61M 2205/18 (2013.01); A61M 2205/3317 (2013.01); A61M 2205/3337 (2013.01); A61M 2205/3344 (2013.01); A61M 2205/3368 (2013.01); A61M 2205/3379 (2013.01); A61M 2205/3569 (2013.01); A61M 2205/3576 (2013.01); A61M 2205/502 (2013.01); A61M 2205/52 (2013.01); A61M 2205/587 (2013.01); A61M 2205/6009 (2013.01); A61M 2205/70 (2013.01); A61M 2205/8206 (2013.01); A61M 2205/8243 (2013.01); A61M 2209/086 (2013.01); A61M 2209/088 (2013.01); A61M 2210/1017 (2013.01); A61M 2210/1085 (2013.01);
Abstract

A Direct Sodium Removal method, apparatus and solution for treating patients in heart failure, and having a glomerular filtration rate greater than 15 mL/min/1.73 m, or residual kidney function corresponding to normal to CKD Stage 4, is provided in which a no or low sodium DSR infusate is administered to the peritoneal cavity for a predetermined dwell period and then removed, thereby removing sodium from the body. The resulting elimination of fluid from the patient by i) functioning of the kidneys through urination and ii) direct removal of osmotic ultrafiltrate from the peritoneal cavity, restores serum sodium concentrations to healthy levels and thereby reduces fluid overload in the patient.

Find Patent Forward Citations

Loading…